光学疾患治療薬市場- 世界の産業規模、シェア、動向、機会、予測、処方タイプ別、治療薬別、エンドユーザー別、地域別、競合別、2020-2030F

光学疾患治療薬の世界市場は、2024年に376億8,000万米ドルと評価され、2030年には603億5,000万米ドルに達すると予測され、予測期間中に8.14％の年間平均成長率（CAGR）で拡大すると予測されています。

眼科疾患または眼障害とも呼ばれる光学疾患は、眼と視覚系に影響を及ぼす幅広い症状を包含します。これらの疾患は、眼球構成要素の構造や機能を損ない、視覚障害、不快感、その他の症状を引き起こします。これらの疾患はあらゆる年齢層に影響を及ぼす可能性があり、重症度も軽度から衰弱性まで様々です。

視力障害の治療法は多岐にわたり、症状の性質や進行度によって異なります。矯正レンズ（眼鏡やコンタクトレンズ）、薬理療法（点眼薬や内服薬）、外科的処置、生活習慣の改善、早期発見と継続的なモニタリングを目的とした定期的な眼科検査などがあります。これらの治療の包括的な目標は、視機能を維持し、眼全体の健康を維持することです。

主な市場促進要因

技術の進歩

主な市場課題

ジェネリック医薬品競合

主な市場動向

患者中心の治療アプローチ

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の光学疾患治療薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 処方箋の種類別（市販薬、処方眼科薬）
  • 治療薬別（加齢黄斑変性、結膜炎、糖尿病黄斑浮腫、糖尿病網膜症、ドライアイ、眼がん、緑内障など）
  • エンドユーザー別（診断センター、眼科クリニック、病院）
  • 企業別（2024）
• 市場マップ

第6章 アジア太平洋地域の光学疾患治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第7章 欧州の光学疾患治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第8章 北米の光学疾患治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第9章 南米の光学疾患治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの光学疾患治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界の光学疾患治療薬市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 PESTEL分析

第16章 競合情勢

• Alcon Inc.
• Novartis ag
• Johnson & Johnson services, Inc.
• Bausch health
• Merck & co. Inc.
• Coherus biosciences, Inc.
• Allergan
• Pfizer, Inc.
• Bayer ag
• Santen pharmaceuticals co. Ltd.
• Genetech, Inc.

第17章 戦略的提言

第18章 調査会社について・免責事項

Global Optical Disorders Drugs Market for optical disorders drugs was valued at USD 37.68 billion in 2024 and is projected to reach USD 60.35 billion by 2030, expanding at a compound annual growth rate (CAGR) of 8.14% during the forecast period. Optical disorders, also referred to as ophthalmic or eye disorders, encompass a broad spectrum of conditions affecting the eyes and the visual system. These disorders can impair the structure or function of ocular components, leading to visual disturbances, discomfort, or additional symptoms. They can affect individuals across all age groups and vary in severity from mild to debilitating.

Treatment options for optical disorders are diverse and depend on the nature and progression of the condition. Interventions may include corrective lenses (eyeglasses or contact lenses), pharmacological therapies (eye drops or oral medications), surgical procedures, lifestyle changes, and routine eye examinations aimed at early detection and ongoing monitoring. The overarching goal of these treatments is to preserve visual function and maintain overall ocular health.

Key Market Drivers

Technological Advancements

Recent technological progress in ophthalmology has significantly shaped the pharmaceutical landscape. One major development is the introduction of sustained-release drug delivery systems that provide controlled and extended medication release, reducing the frequency of administration. A notable example is Roche's Susvimo (ranibizumab injection), which received FDA approval in February 2025 for the treatment of diabetic macular edema (DME). It is the first and only FDA-approved therapy shown to maintain vision in DME patients with fewer treatments compared to standard care.

Nanotechnology is playing a critical role in enhancing ocular drug delivery. Nanogels and other nano-sized carriers have demonstrated improved tissue penetration and bioavailability, particularly in treating anterior segment conditions such as glaucoma, cataracts, dry eye syndrome, and bacterial keratitis.

Advancements in topical ophthalmic formulations are also contributing to market growth. For example, lipid-based eye drops have been developed to effectively manage evaporative dry eye disease by stabilizing the tear film and reducing tear evaporation.

Biotechnology has facilitated the emergence of gene therapies that target specific molecular pathways involved in various ocular diseases. These therapies have shown potential in delivering long-term visual improvements for patients suffering from inherited or degenerative retinal conditions.

Key Market Challenges

Generic Competition

The growing presence of generic drugs poses a significant challenge for brand-name pharmaceutical companies operating in the optical disorders segment. Once patent protections expire, lower-cost generics enter the market, often at substantially reduced prices, impacting revenue streams of original drug manufacturers. Patients and healthcare providers frequently opt for generics due to their affordability, leading to decreased market share for innovator products.

The rapid adoption of generics can lead to price erosion and force originator companies to reduce prices or offer discounts to maintain competitiveness. This shift adversely affects profit margins and limits the ability to reinvest in research and development (R&D). Moreover, the loss of exclusivity following patent expiry often results in diminished market dominance.

This competitive pressure can discourage pharmaceutical firms from pursuing new drug innovations in the ophthalmic space, given the reduced commercial incentives once generics become viable. As a result, companies must carefully balance R&D investments with strategic planning to mitigate the risks associated with generic competition.

Key Market Trends

Patient-Centric Treatment Approaches

There is a growing trend toward tailoring ophthalmic treatment plans to align with individual patient preferences and lifestyles. Healthcare providers are increasingly considering factors such as daily routines, treatment goals, and comfort when selecting medications and therapeutic approaches.

Patients express varied preferences for modes of drug administration-some favor eye drops, while others may opt for ointments or less frequent dosing schedules. In response, pharmaceutical companies are expanding their product portfolios to include a range of delivery formats designed for ease of use and integration into daily life.

User-friendly packaging and intuitive application mechanisms are being developed to improve adherence to treatment protocols. Additionally, reducing the occurrence of side effects is a major focus in drug development, as improved tolerability leads to higher compliance and better clinical outcomes.

Flexibility in dosing is also highly valued by patients. Drugs offering once-daily or extended dosing intervals provide greater convenience and enhance patient autonomy. The industry is further shifting toward collaborative care models, emphasizing patient education and shared decision-making between patients and healthcare providers. This approach ensures that treatment plans reflect individual values and objectives, leading to increased satisfaction and better management of eye disorders.

Key Market Players

• Alcon Inc.
• Novartis ag
• Johnson & Johnson services, Inc.
• Bausch health
• Merck & co. Inc.
• Coherus biosciences, Inc.
• Allergan
• Pfizer, Inc.
• Bayer ag
• Santen pharmaceuticals co. Ltd.
• Genetech, Inc.

Report Scope:

In this report, the Global Optical Disorders Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Optical Disorders Drugs Market, By Prescription Type:

• Over-The-Counter Drugs
• Prescription Ophthalmic Drugs

Optical Disorders Drugs Market, By Therapeutics:

• Age-Related Macular Degeneration
• Conjunctivitis
• Diabetic Macular Edema
• Diabetic Retinopathy
• Dry Eye
• Eye Cancer
• Glaucoma
• Others

Optical Disorders Drugs Market, By End User:

• Diagnostic Centers
• Eye Clinics
• Hospitals

Optical Disorders Drugs Market, By region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Optical Disorders Drugs Market.

Available Customizations:

Global Optical Disorders Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Optical Disorders Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Prescription Type (Over-The-Counter Drugs, Prescription Ophthalmic Drugs)
  • 5.2.2. By Therapeutics (Age-Related Macular Degeneration, Conjunctivitis, Diabetic Macular Edema, Diabetic Retinopathy, Dry Eye, Eye Cancer, Glaucoma, others)
  • 5.2.3. By End User (Diagnostic Centers, Eye Clinics, Hospitals)
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Optical Disorders Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Prescription Type
  • 6.2.2. By Therapeutics
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Optical Disorders Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Prescription Type
      • 6.3.1.2.2. By Therapeutics
      • 6.3.1.2.3. By End User
  • 6.3.2. India Optical Disorders Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Prescription Type
      • 6.3.2.2.2. By Therapeutics
      • 6.3.2.2.3. By End User
  • 6.3.3. Australia Optical Disorders Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Prescription Type
      • 6.3.3.2.2. By Therapeutics
      • 6.3.3.2.3. By End User
  • 6.3.4. Japan Optical Disorders Drugs Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Prescription Type
      • 6.3.4.2.2. By Therapeutics
      • 6.3.4.2.3. By End User
  • 6.3.5. South Korea Optical Disorders Drugs Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Prescription Type
      • 6.3.5.2.2. By Therapeutics
      • 6.3.5.2.3. By End User

7. Europe Optical Disorders Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Prescription Type
  • 7.2.2. By Therapeutics
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Optical Disorders Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Prescription Type
      • 7.3.1.2.2. By Therapeutics
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany Optical Disorders Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Prescription Type
      • 7.3.2.2.2. By Therapeutics
      • 7.3.2.2.3. By End User
  • 7.3.3. Spain Optical Disorders Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Prescription Type
      • 7.3.3.2.2. By Therapeutics
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Optical Disorders Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Prescription Type
      • 7.3.4.2.2. By Therapeutics
      • 7.3.4.2.3. By End User
  • 7.3.5. United Kingdom Optical Disorders Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Prescription Type
      • 7.3.5.2.2. By Therapeutics
      • 7.3.5.2.3. By End User

8. North America Optical Disorders Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Prescription Type
  • 8.2.2. By Therapeutics
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Optical Disorders Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Prescription Type
      • 8.3.1.2.2. By Therapeutics
      • 8.3.1.2.3. By End User
  • 8.3.2. Mexico Optical Disorders Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Prescription Type
      • 8.3.2.2.2. By Therapeutics
      • 8.3.2.2.3. By End User
  • 8.3.3. Canada Optical Disorders Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Prescription Type
      • 8.3.3.2.2. By Therapeutics
      • 8.3.3.2.3. By End User

9. South America Optical Disorders Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Prescription Type
  • 9.2.2. By Therapeutics
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Optical Disorders Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Prescription Type
      • 9.3.1.2.2. By Therapeutics
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Optical Disorders Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Prescription Type
      • 9.3.2.2.2. By Therapeutics
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Optical Disorders Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Prescription Type
      • 9.3.3.2.2. By Therapeutics
      • 9.3.3.2.3. By End User

10. Middle East and Africa Optical Disorders Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Prescription Type
  • 10.2.2. By Therapeutics
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Optical Disorders Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Prescription Type
      • 10.3.1.2.2. By Therapeutics
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Optical Disorders Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Prescription Type
      • 10.3.2.2.2. By Therapeutics
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Optical Disorders Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Prescription Type
      • 10.3.3.2.2. By Therapeutics
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Optical Disorders Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Alcon Inc.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (As Reported)
  • 16.1.5. Recent Developments
  • 16.1.6. Key Personnel Details
  • 16.1.7. SWOT Analysis
• 16.2. Novartis ag
• 16.3. Johnson & Johnson services, Inc.
• 16.4. Bausch health
• 16.5. Merck & co. Inc.
• 16.6. Coherus biosciences, Inc.
• 16.7. Allergan
• 16.8. Pfizer, Inc.
• 16.9. Bayer ag
• 16.10. Santen pharmaceuticals co. Ltd.
• 16.11. Genetech, Inc.

17. Strategic Recommendations

18. About Us & Disclaimer